Vincent J. Milano's most recent trade in Biocryst Pharmaceuticals Inc. was a trade of 676 Common Stock done at an average price of $8.3 . Disclosure was reported to the exchange on Aug. 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 8.31 per share. | 29 Aug 2025 | 676 | 90,436 (0%) | 0% | 8.3 | 5,618 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 27,181 | 27,181 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 12,500 | 89,760 (0%) | 0% | 0 | Common Stock | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 42,350 | 42,350 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 11,580 | 11,580 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2025 | 4,793 | 17,316 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2025 | 4,793 | 0 | - | - | Restricted Stock Units | |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 10.75 per share. | 30 May 2025 | 523 | 77,260 (0%) | 0% | 10.7 | 5,622 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 8.61 per share. | 28 Feb 2025 | 653 | 76,737 (0%) | 0% | 8.6 | 5,622 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 7.50 per share. | 29 Nov 2024 | 750 | 76,084 (0%) | 0% | 7.5 | 5,625 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 8.69 per share. | 30 Aug 2024 | 647 | 75,334 (0%) | 0% | 8.7 | 5,622 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 49,933 | 49,933 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 6,820 | 74,687 (0%) | 0% | 0 | Common Stock | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 4,793 | 4,793 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,660 | 12,523 (0%) | 0% | - | Common Stock | |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 6.46 per share. | 31 May 2024 | 870 | 67,867 (0%) | 0% | 6.5 | 5,620 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Purchase of securities on an exchange or from another person at price $ 6.25 per share. | 20 May 2024 | 15,000 | 66,997 (0%) | 0% | 6.3 | 93,750 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 5.63 per share. | 29 Feb 2024 | 999 | 51,997 (0%) | 0% | 5.6 | 5,624 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 39,072 | 39,072 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 16,745 | 49,251 (0%) | 0% | 0 | Common Stock | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,660 | 4,660 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2023 | 4,507 | 7,863 (0%) | 0% | - | Common Stock | |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 8.27 per share. | 31 May 2023 | 680 | 32,506 (0%) | 0% | 8.3 | 5,624 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 8.85 per share. | 28 Feb 2023 | 635 | 31,826 (0%) | 0% | 8.9 | 5,620 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 13.36 per share. | 30 Nov 2022 | 421 | 31,191 (0%) | 0% | 13.4 | 5,625 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 13.90 per share. | 31 Aug 2022 | 404 | 30,770 (0%) | 0% | 13.9 | 5,616 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,022 | 30,022 | - | - | Automatic Stock Option Grant | |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 12,866 | 30,366 (0%) | 0% | 0 | Common Stock | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 15,750 | 15,750 | - | - | Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,507 | 4,507 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Vincent J. Milano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 3,356 | 3,356 (0%) | 0% | - | Common Stock | |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Purchase of securities on an exchange or from another person at price $ 12.19 per share. | 24 Nov 2021 | 7,500 | 17,500 (0%) | 0% | 12.2 | 91,425 | Common Stock |
| Biocryst Pharmaceuticals Inc | Vincent J. Milano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2021 | 66,667 | 66,667 | - | - | Non-Qualified Stock Option |